{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T23:41:40Z","timestamp":1781739700968,"version":"3.54.5"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,4,26]],"date-time":"2016-04-26T00:00:00Z","timestamp":1461628800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.eururo.2016.04.019","type":"journal-article","created":{"date-parts":[[2016,5,6]],"date-time":"2016-05-06T17:17:09Z","timestamp":1462555029000},"page":"319-327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer"],"prefix":"10.1016","volume":"71","author":[{"given":"Khalid","family":"Saeed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesa","family":"Rahkama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuli","family":"Eldfors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Bychkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Patrick","family":"Mpindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagwan","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lassi","family":"Paavolainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tero","family":"Aittokallio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Heckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krister","family":"Wennerberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna M.","family":"Peehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuomas","family":"Mirtti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antti","family":"Rannikko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olli","family":"Kallioniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4ivi","family":"\u00d6stling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taija M.","family":"af H\u00e4llstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2016.04.019_bib0130","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","article-title":"EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"65","author":"Heidenreich","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.04.019_bib0135","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.eururo.2013.09.046","article-title":"EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013","volume":"65","author":"Heidenreich","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.04.019_bib0140","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.eururo.2011.08.026","article-title":"Contemporary role of androgen deprivation therapy for prostate cancer","volume":"61","author":"Pagliarulo","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.04.019_bib0145","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","article-title":"Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth","volume":"68","author":"Montgomery","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2016.04.019_bib0150","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2016.04.019_bib0155","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2016.04.019_bib0160","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2016.04.019_bib0165","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2016.04.019_bib0170","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.eururo.2012.08.058","article-title":"Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme","volume":"63","author":"Heidenreich","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.04.019_bib0175","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.eururo.2013.06.042","article-title":"Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone","volume":"65","author":"Schrader","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.04.019_bib0180","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2016.04.019_bib0185","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/jcb.10764","article-title":"In vitro culturing and characteristics of transit amplifying epithelial cells from human prostate tissue","volume":"91","author":"Uzgare","year":"2004","journal-title":"J Cell Biochem"},{"issue":"Suppl","key":"10.1016\/j.eururo.2016.04.019_bib0190","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S1040-8428(03)00059-3","article-title":"Epithelial cell differentiation in the human prostate epithelium: implications for the pathogenesis and therapy of prostate cancer","volume":"46","author":"van Leenders","year":"2003","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.eururo.2016.04.019_bib0195","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/(SICI)1097-0045(199602)28:2<98::AID-PROS4>3.0.CO;2-J","article-title":"Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model","volume":"28","author":"Bonkhoff","year":"1996","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2016.04.019_bib0200","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.stem.2012.03.009","article-title":"The PSA(-\/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration","volume":"10","author":"Qin","year":"2012","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.eururo.2016.04.019_bib0205","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ajpath.2011.10.036","article-title":"ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells","volume":"180","author":"Liu","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1016\/j.eururo.2016.04.019_bib0210","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/ncb3047","article-title":"Single luminal epithelial progenitors can generate prostate organoids in culture","volume":"16","author":"Chua","year":"2014","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.eururo.2016.04.019_bib0215","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.cell.2014.08.016","article-title":"Organoid cultures derived from patients with advanced prostate cancer","volume":"159","author":"Gao","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.eururo.2016.04.019_bib0220","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1158\/2159-8290.CD-13-0350","article-title":"Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia","volume":"3","author":"Pemovska","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2016.04.019_bib0225","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1038\/srep05193","article-title":"Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies","volume":"4","author":"Yadav","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.eururo.2016.04.019_bib0230","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1038\/bjc.2014.204","article-title":"Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed","volume":"110","author":"Lee","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2016.04.019_bib0235","doi-asserted-by":"crossref","first-page":"20035","DOI":"10.1073\/pnas.1213241109","article-title":"Conditionally reprogrammed cells represent a stem-like state of adult epithelial cells","volume":"109","author":"Suprynowicz","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eururo.2016.04.019_bib0240","first-page":"6052","article-title":"Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity","volume":"60","author":"Lebedeva","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2016.04.019_bib0245","first-page":"1567","article-title":"Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers","volume":"148","author":"Krajewska","year":"1996","journal-title":"Am J Pathol"},{"key":"10.1016\/j.eururo.2016.04.019_bib0250","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/S0022-5347(05)68095-0","article-title":"p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy","volume":"162","author":"Stackhouse","year":"1999","journal-title":"J Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228381630080X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228381630080X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:05:38Z","timestamp":1759583138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030228381630080X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S030228381630080X"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2016.04.019","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2016.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association of Urology. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}